Estee Lauder Companies Inc vs Humana Inc — how do they compare? Estee Lauder Companies Inc trades at $97.42 (market cap $34.17B), while Humana Inc trades at $437.71 (market cap $46.49B). The key difference: Humana Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Humana Inc for 53 Days on average.
| EL | HUM | |
|---|---|---|
Market Cap | $34.17B | $46.49B |
Volume | 3,921,497 | 2,567,704 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $409.85 |
52-Week Low | $67.23 | $163.67 |
Typical Hold Time | 122 Days | 53 Days |
Enterprise Value | $39.92B | $53.84B |
Dividend Yield | 1.48% | 0.91% |
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows improving earnings momentum with three consecutive quarterly beats, though 2025 results showed a net loss of $1.13B on $14.33B revenue. Analyst consensus is mixed with 48% buy ratings and a $103 price target, while recent news highlights AI partnerships and leadership changes driving strategic repositioning.
The stock presents a turnaround opportunity with strong brand positioning and digital initiatives, but faces execution risks from recent profitability challenges and high debt levels. Near-term catalysts include Q3 earnings and continued margin recovery, though competitive pressures and macroeconomic sensitivity remain headwinds for the luxury beauty sector.
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →